Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilpivirine rollover study in pediatric HIV-1 participants
2014-002471-28Phase 2
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rilpivirine in Human immunodeficiency virus infection type 1, sponsored by Janssen Pharmaceutical. Primary endpoint: Number of participants with adverse events related to rilpivirine.
02
Drugs
rilpivirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2014-002471-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002471-28.